KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Assets (2016 - 2025)

Jazz Pharmaceuticals has reported Current Assets over the past 16 years, most recently at $4.2 billion for Q4 2025.

  • Quarterly results put Current Assets at $4.2 billion for Q4 2025, down 10.0% from a year ago — trailing twelve months through Dec 2025 was $4.2 billion (down 10.0% YoY), and the annual figure for FY2025 was $4.2 billion, down 10.0%.
  • Current Assets for Q4 2025 was $4.2 billion at Jazz Pharmaceuticals, up from $3.8 billion in the prior quarter.
  • Over the last five years, Current Assets for JAZZ hit a ceiling of $4.6 billion in Q4 2024 and a floor of $2.5 billion in Q1 2022.
  • Median Current Assets over the past 5 years was $3.2 billion (2021), compared with a mean of $3.3 billion.
  • Biggest five-year swings in Current Assets: soared 108.67% in 2021 and later decreased 21.03% in 2022.
  • Jazz Pharmaceuticals' Current Assets stood at $2.6 billion in 2021, then fell by 0.2% to $2.6 billion in 2022, then skyrocketed by 31.82% to $3.4 billion in 2023, then skyrocketed by 34.74% to $4.6 billion in 2024, then fell by 10.0% to $4.2 billion in 2025.
  • The last three reported values for Current Assets were $4.2 billion (Q4 2025), $3.8 billion (Q3 2025), and $3.4 billion (Q2 2025) per Business Quant data.